FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2653070086> ?p ?o ?g. }

• W2653070086 endingPage "977" @default.
• W2653070086 startingPage "968" @default.
• W2653070086 abstract "As biosimilars enter the market, comparisons of product quality are needed. Manufacturing differences may lead to differences in critical quality attributes, which affect efficacy. Therefore, critical quality attributes (structure and biological activity) of Remicade® and of 2 biosimilar products (Flixabi®/Renflexis® and Remsima®/Inflectra®) were determined. We assessed binding to tumor necrosis factor in a fluorescence competitive binding assay; potency in a luciferase reporter gene assay; percentages of galactosylated glycan, afucose plus high mannosylated glycans, and charged glycan; FcγRIIIa (CD16) binding (assessed by 3 methods); and antibody-dependent cell-mediated cytotoxicity (ADCC) in the NK92-CD16a cell line and in peripheral blood mononuclear cells (PBMC). The results of Fab-related activity were similar for all products. Compared with Remicade®, Flixabi® had a lower percentage of charged glycan, and Remsima® had a higher percentage of galactosylated glycan and a lower percentage of afucose plus high mannosylated glycans. Whereas Remsima® and Remicade® are expressed in a Sp2/0 cell line, Flixabi® is expressed in a CHO cell line. Despite this difference, galactosylated glycans from the 3 products were not correlated with the expression system. The results of all 3 methods used in this study indicated that FcγRIIIa binding was lower with Remsima® than with Remicade®. The percentage of ADCC in NK92-CD16a cells was lower with Remsima® and higher with Flixabi® compared with Remicade®, but was similar for all 3 products in PBMC. Surface expression of CD16 was 5.7-fold greater on NK92-CD16a cells than on PBMC. Combined percentages of afucosylated and high mannosylated glycans were positively correlated with FcγRIIIa binding and ADCC in NK92-CD16 cells, while no correlation was observed in PBMC." @default.
• W2653070086 created "2017-06-30" @default.
• W2653070086 creator A5006689099 @default.
• W2653070086 creator A5027788650 @default.
• W2653070086 creator A5043656201 @default.
• W2653070086 creator A5044399319 @default.
• W2653070086 creator A5048484720 @default.
• W2653070086 creator A5074418576 @default.
• W2653070086 creator A5076699095 @default.
• W2653070086 date "2017-06-22" @default.
• W2653070086 modified "2023-09-24" @default.
• W2653070086 title "Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®" @default.
• W2653070086 cites W1552963759 @default.
• W2653070086 cites W1965347749 @default.
• W2653070086 cites W2017355698 @default.
• W2653070086 cites W2023765040 @default.
• W2653070086 cites W2035753258 @default.
• W2653070086 cites W2067367025 @default.
• W2653070086 cites W2078353854 @default.
• W2653070086 cites W2106183724 @default.
• W2653070086 cites W2122208441 @default.
• W2653070086 cites W2136007354 @default.
• W2653070086 cites W2137354517 @default.
• W2653070086 cites W2141073877 @default.
• W2653070086 cites W2160264356 @default.
• W2653070086 cites W2160798258 @default.
• W2653070086 cites W2175291039 @default.
• W2653070086 cites W2567453335 @default.
• W2653070086 doi "https://doi.org/10.1080/19420862.2017.1337620" @default.
• W2653070086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5540080" @default.
• W2653070086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28640663" @default.
• W2653070086 hasPublicationYear "2017" @default.
• W2653070086 type Work @default.
• W2653070086 sameAs 2653070086 @default.
• W2653070086 citedByCount "45" @default.
• W2653070086 countsByYear W26530700862018 @default.
• W2653070086 countsByYear W26530700862019 @default.
• W2653070086 countsByYear W26530700862020 @default.
• W2653070086 countsByYear W26530700862021 @default.
• W2653070086 countsByYear W26530700862022 @default.
• W2653070086 countsByYear W26530700862023 @default.
• W2653070086 crossrefType "journal-article" @default.
• W2653070086 hasAuthorship W2653070086A5006689099 @default.
• W2653070086 hasAuthorship W2653070086A5027788650 @default.
• W2653070086 hasAuthorship W2653070086A5043656201 @default.
• W2653070086 hasAuthorship W2653070086A5044399319 @default.
• W2653070086 hasAuthorship W2653070086A5048484720 @default.
• W2653070086 hasAuthorship W2653070086A5074418576 @default.
• W2653070086 hasAuthorship W2653070086A5076699095 @default.
• W2653070086 hasBestOaLocation W26530700861 @default.
• W2653070086 hasConcept C108625454 @default.
• W2653070086 hasConcept C109316439 @default.
• W2653070086 hasConcept C114684123 @default.
• W2653070086 hasConcept C137061746 @default.
• W2653070086 hasConcept C147483822 @default.
• W2653070086 hasConcept C153911025 @default.
• W2653070086 hasConcept C167672396 @default.
• W2653070086 hasConcept C185592680 @default.
• W2653070086 hasConcept C202751555 @default.
• W2653070086 hasConcept C203014093 @default.
• W2653070086 hasConcept C206212055 @default.
• W2653070086 hasConcept C2777313579 @default.
• W2653070086 hasConcept C2781462264 @default.
• W2653070086 hasConcept C40677261 @default.
• W2653070086 hasConcept C54355233 @default.
• W2653070086 hasConcept C553184892 @default.
• W2653070086 hasConcept C55493867 @default.
• W2653070086 hasConcept C81885089 @default.
• W2653070086 hasConcept C86803240 @default.
• W2653070086 hasConceptScore W2653070086C108625454 @default.
• W2653070086 hasConceptScore W2653070086C109316439 @default.
• W2653070086 hasConceptScore W2653070086C114684123 @default.
• W2653070086 hasConceptScore W2653070086C137061746 @default.
• W2653070086 hasConceptScore W2653070086C147483822 @default.
• W2653070086 hasConceptScore W2653070086C153911025 @default.
• W2653070086 hasConceptScore W2653070086C167672396 @default.
• W2653070086 hasConceptScore W2653070086C185592680 @default.
• W2653070086 hasConceptScore W2653070086C202751555 @default.
• W2653070086 hasConceptScore W2653070086C203014093 @default.
• W2653070086 hasConceptScore W2653070086C206212055 @default.
• W2653070086 hasConceptScore W2653070086C2777313579 @default.
• W2653070086 hasConceptScore W2653070086C2781462264 @default.
• W2653070086 hasConceptScore W2653070086C40677261 @default.
• W2653070086 hasConceptScore W2653070086C54355233 @default.
• W2653070086 hasConceptScore W2653070086C553184892 @default.
• W2653070086 hasConceptScore W2653070086C55493867 @default.
• W2653070086 hasConceptScore W2653070086C81885089 @default.
• W2653070086 hasConceptScore W2653070086C86803240 @default.
• W2653070086 hasIssue "6" @default.
• W2653070086 hasLocation W26530700861 @default.
• W2653070086 hasLocation W26530700862 @default.
• W2653070086 hasLocation W26530700863 @default.
• W2653070086 hasLocation W26530700864 @default.
• W2653070086 hasOpenAccess W2653070086 @default.
• W2653070086 hasPrimaryLocation W26530700861 @default.
• W2653070086 hasRelatedWork W2022264081 @default.
• W2653070086 hasRelatedWork W2040553942 @default.
• W2653070086 hasRelatedWork W2053119527 @default.

• next